Dr. Wesley T. Mizutani, MD

Dr. Mizutani practices at Healthcare Partners Medical Group in Huntington Beach, California.

Dr. Mizutani's NPI, 1699774919, was assigned on July 19, 2005. Dr. Mizutani graduated from David Geffen School of Medicine at UCLA in 1982. Dr. Mizutani holds California license A40745.

Dr. Mizutani's primary practice is Healthcare Partners Medical Group, at 19066 Magnolia St, Huntington Beach, CA 92646 in Orange County. The practice phone is (213) 623-2225.

Dr. Mizutani's primary practice is Healthcare Partners Medical Group in Huntington Beach, California. The medical group on file is Optum - Downtown Los Angeles. Dmand AI also links Dr. Mizutani to 4 more medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mizutani practices, 2 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Mizutani's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Mizutani is licensed in California.

Dmand AI lists arthritis, lupus, muscle pain, fibromyalgia, and limb pain and rheumatoid arthritis among the conditions Dr. Mizutani treats.

CMS data shows 63 Medicare services from Dr. Mizutani across 2 procedure codes in 2024, all of them office visits, for 44 Medicare patients. Medicare paid $4,772 for them. Every service was in an office.

CMS counts 44 Medicare patients who saw Dr. Mizutani in 2024. The largest group is 65 to 74, with 23 patients. 75% of them have arthritis, and 73% have high cholesterol. 43% are also on Medicaid. Their average risk score is 1.39, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Mizutani's median patient age at 67, with 80% women.

In 2024, Dr. Mizutani wrote 886 Medicare Part D claims for 152 patients. 86% of them were for generic drugs. CMS names the drug for 702 of them, across 22 drugs with 11 or more claims each, at $353,653 in total drug cost. In 2023, CMS named 832 claims across 23 drugs.

Dr. Mizutani accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mizutani as offering telehealth.

Dmand AI links Dr. Mizutani to 2 clinical trials. Conditions studied include Fibromyalgia, Lupus Erythematosus, Systemic and Connective Tissue Diseases. Open Payments lists research payments to Dr. Mizutani that name 2 trials.

CMS Open Payments shows 258 general payments to Dr. Mizutani from 19 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 63% of the total. Celgene Corporation paid the most, $40,407. It also lists 2 research payments totaling $3,120 from 2016 to 2018, naming 2 clinical trials.

Dmand AI lists 1 award for Dr. Mizutani, most recently CMS Stage 1 EHR in 2013.

Dr. Mizutani graduated from David Geffen School of Medicine at UCLA in 1982.

Dr. Mizutani is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.